# A Study to Investigate the Efficacy of LT-02 in Patients With Mesalazine Refractory Ulcerative Colitis

> **NCT01011322** · PHASE2 · UNKNOWN · sponsor: **Lipid Therapeutics GmbH** · enrollment: 156 (actual)

## Conditions studied

- Ulcerative Colitis
- Large Intestine
- Diarrhea
- Abdominal Pain

## Interventions

- **DRUG:** LT-02
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01011322
- **Lead sponsor:** Lipid Therapeutics GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-12
- **Primary completion:** 2011-07
- **Final completion:** 2012-02
- **Target enrollment:** 156 (ACTUAL)
- **Last updated:** 2011-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01011322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01011322, "A Study to Investigate the Efficacy of LT-02 in Patients With Mesalazine Refractory Ulcerative Colitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01011322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*